Northend, M; Wilson, W; Osborne, W; Fox, CP; Davies, AJ; El-Sharkawi, D; Phillips, EH; ... Townsend, WM; + view all Northend, M; Wilson, W; Osborne, W; Fox, CP; Davies, AJ; El-Sharkawi, D; Phillips, EH; Sim, HW; Sadullah, S; Shah, N; Peng, YY; Qureshi, I; Addada, J; Mora, RF; Phillips, N; Kuhnl, A; Davies, E; Wrench, DJ; McKay, P; Karpha, I; Cowley, A; Karim, R; Challenor, S; Singh, V; Burton, C; Auer, R; Williams, C; Cunningham, J; Broom, A; Arasaretnam, A; Roddie, C; Menne, T; Townsend, WM; - view fewer (2022) Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Advances , 6 (9) pp. 2920-2926. 10.1182/bloodadvances.2021005953.